文献速递炎症性肠病

粪便钙卫蛋白对溃疡性结肠炎达标治疗监测的预后价值

Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-04

本文为GEMINI 1/GEMINI LTS(N=620)与VARSITY(N=771)试验的事后分析,评估生物制剂诱导后粪便钙卫蛋白(FCP)识别内镜活动与组织学炎症的横断面准确性及其预后价值。诱导后FCP≤250 μg/g vs >250 μg/g与第52周临床、内镜及组织学缓解概率更高相关,且7年内结肠切除与UC相关住院风险更低。

要点

  • 诱导后FCP识别内镜活动与组织学炎症的横断面准确性中等(63%-79%)。
  • 诱导后FCP≤250 μg/g vs >250 μg/g与第52周临床缓解(OR 4.03)、内镜缓解(OR 4.26)概率更高相关。
  • FCP≤250 μg/g组7年内结肠切除(HR 0.296)与UC相关住院(HR 0.583)风险更低。

核心结论

  • FCP识别疾病活动的横断面准确性仅为中等,但诱导后FCP≤250 μg/g vs >250 μg/g与长期临床、内镜及组织学缓解概率增加及结肠切除和UC相关住院概率降低相关。

研究设计与样本

  • GEMINI 1/GEMINI LTS(N=620)与VARSITY(N=771)试验的事后分析,评估生物制剂诱导后FCP的横断面准确性与预后性能。

主要发现

  • FCP识别内镜活动与组织学炎症的横断面准确性为63%-79%。
  • 诱导后FCP≤250 μg/g vs >250 μg/g与第52周临床缓解(OR 4.03;95%CI 2.78-5.85)、内镜缓解(OR 4.26;95%CI 2.83-6.40)、组织学缓解(Robarts组织病理学指数:OR 5.54;95%CI 3.77-8.14;Geboes分级:OR 6.42;95%CI 4.02-10.26)概率更高相关。
  • FCP≤250 μg/g组7年内结肠切除(HR 0.296;95%CI 0.130-0.677)与UC相关住院(HR 0.583;95%CI 0.389-0.874)风险更低。
  • 与结肠切除的关联在诱导后症状缓解或内镜改善的患者中以及基线FCP升高的患者中亦显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the value of post-induction fecal calprotectin (FCP) concentration as a biomarker in patients with ulcerative colitis (UC) treated with a biologic. METHODS: This post hoc analysis of the GEMINI 1/GEMINI LTS (N = 620) and VARSITY (N = 771) trials evaluated the cross-sectional accuracy of post-induction FCP in identifying endoscopic activity and histologic inflammation, and the prognostic performance of FCP in identifying patients most likely to achieve endoscopic and histologic remission or require colectomy and UC-related hospitalization. RESULTS: The cross-sectional accuracy of FCP in identifying endoscopic activity and histologic inflammation was modest (63%-79%). However, a post-induction FCP concentration of ≤250 μg/g vs >250 μg/g was associated with a substantially higher probability of achieving clinical remission (odds ratio [OR], 4.03; 95% confidence interval [CI], 2.78-5.85), endoscopic remission (OR, 4.26; 95% CI, 2.83-6.40), and histologic remission (Robarts Histopathology Index: OR, 5.54; 95% CI, 3.77-8.14; Geboes grade: OR, 6.42; 95% CI, 4.02-10.26) at week 52 and a lower probability of colectomy over 7 years (hazard ratio, 0.296; 95% CI, 0.130-0.677) and UC-related hospitalization (hazard ratio, 0.583; 95% CI, 0.389-0.874). The association with colectomy was significant even among patients in symptomatic remission or with endoscopic improvement post-induction, and among patients with elevated FCP at baseline. CONCLUSIONS: Although FCP had only modest cross-sectional accuracy in identifying disease activity, an FCP concentration of ≤250 μg/g vs >250 μg/g was associated with increased probability of achieving long-term clinical, endoscopic, and histologic remission, and reduced probability of colectomy and UC-related hospitalization (ClinicalTrials.gov: NCT00783718, NCT00790933, NCT02497469).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Feagan BG, Sands BE, et al. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022. PMID: 35934286. doi:10.1016/j.cgh.2022.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。